EUCTR2011-002865-39-DE进行中（未招募）不适用
An open label, multicenter phase II study of intravenous SAR3419, an anti-CD19 antibody-maytansine conjugate, in combination with rituximab in patients with relapsed or refractory Diffuse Large B Cell lymphomas
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Histologically diagnosis of DLBCL
- •- Relapsed or refractory after at least one standard treatment including rituximab
- •- CD19 and CD20 positive disease
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •- No bi-dimensionally measurable lesion by CT scan (defined as presence of at least one tumor mass measuring >1.5 x 1.5 cm)
研究者
相似试验
进行中（未招募）
不适用
Combination of SAR3419 and rituximab in relapsed/refractory Diffuse Large B Cell LymphomaDiffuse large B-cell lymphomaMedDRA version: 14.1Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002865-39-SEsanofi-aventis recherche et développement50
进行中（未招募）
不适用
Combination of SAR3419 and rituximab in relapsed/refractory Diffuse Large B Cell LymphomaDiffuse large B-cell lymphomaMedDRA version: 14.1Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002865-39-ATsanofi-aventis recherche et développement
已完成
2 期
A Phase IB/II, open label, multicenter study of INC280 administered orally in combination with gefitinib in adult patients with EGFR mutated, c-MET-amplified non-small cell lung cancer who have progressed after EGFR inhibitor treatment (CINC280X2202)10038666lung cancernon-small cell lung cancerNL-OMON41765ovartis8
进行中（未招募）
1 期
A clinical study with INC280 in combination with gefitinib in patients with non-small cell lung canceron-Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002569-39-DEovartis Pharma Services AG148
进行中（未招募）
1 期
A clinical study with INC280 in combination with gefitinib in patients with non-small cell lung cancerEUCTR2011-002569-39-ITovartis Farma58